A MEETING OF THE BOARD OF DIRECTORS

To be held in public on Thursday 22 April 2021 at 09:30am

via Life size video link

AGENDA

No.	ltem	Action	Paper	Lead	Mins	S.O
1.	Apologies for absence	Note	Verbal	TG		
2.	Declarations of interest	Note	Verbal	TG		
3.	Minutes of the meeting held on 25 March 2021	Approve	Enclosed	TG	00:05	
4.	Matters arising and action points	Note	Enclosed	TG	00:05	
5.	Chief Executive's Report	Note	Enclosed	DP	00:15	All
6.	Staff survey	Present	Enclosed	SD	00:15	5
7.	Learning from deaths	Assurance	Enclosed	LW	00:05	1
8.	Fit and proper persons annual report	Assurance	Enclosed	TG	00:05	5
9.	Integrated Performance Report	Assurance	Enclosed	AS	00:10	1
10.	Finance Report	Assurance	To follow	JW	00:10	7
11.	Report from the audit and risk committee	Assurance	Enclosed	NH	00:10	6
12.	Identify any risk items arising from the agenda	Note	Verbal	TG		6
13.	AOB	Note	Verbal	TG		

14. Date of the next meeting – Thursday 27 May 2021 09:30am





MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST MINUTES OF THE MEETING OF THE BOARD OF DIRECTORS HELD ON THURSDAY 25 MARCH 2021 (via video link)

Attendees: Tessa Green (TG) Chairman

David Probert (DP) Chief executive

Vineet Bhalla (VB) Non-executive director Andrew Dick (AD) Non-executive director Ros Given-Wilson (RGW) Non-executive director Nick Hardie (NH) Non-executive director David Hills (DH) Non-executive director Richard Holmes (RH) Non-executive director Sumita Singha (SS) Non-executive director Adrian Morris (AM) Non-executive director

Johanna Moss (JM) Director of strategy & partnerships
Peng Khaw (PK) Director of research & development

Tracy Luckett (TL)

Jon Spencer (JS)

Louisa Wickham (LW)

Jonathan Wilson (JW)

Director of nursing and AHPs

Chief operating officer

Medical director

Chief financial officer

In attendance: Sandi Drewett (SD)

Sandi Drewett (SD)

Helen Essex (HE)

Jamie Henderson (JH)

Director of workforce & OD

Company secretary (minutes)

Deputy general counsel

Kieran McDaid (KM) Director of estates, major projects and capital

Nick Roberts (NR)

Ian Tombleson (IT)

Kate Falkner (KF)

Chief information officer

Director of quality and safety

Head of nursing, City Road

Justin Betts (JB) Deputy CFO

Lindsey Sokolich (LS) Deputy director of strategy

Governors: John Sloper Public governor, Beds & Herts
Andrew Clark Public governor, Beds & Herts

Ian WilsonPublic governor, NWLRichard CollinsPatient governorKimberley JacksonPublic governor, SWLRob JonesPatient governorPaul MurphyPublic governor, NCLJane BushPublic governor, NCLRoy HendersonPatient governor

Tricia Smikle Nominated governor, RNIB
Una O'Halloran Nominated governor, LBI
John Russell Public governor, NEL & Essex

21/2552 Apologies for absence

There were no apologies.





21/2553 Declarations of interest

There were no declarations of interests.

21/2554 Minutes of the last meeting

The minutes of the meeting held on the 25 February 2021 were agreed as an accurate record.

21/2555 Matters arising and action points

TL advised that a full update on the leading and guiding group would be provided at the April meeting. The trust is expecting further national guidance on social distancing but there are no specific issues to report at the moment. TG formally thanked the volunteers for the work they are doing to assist patients.

TL to update the next meeting.

Full report on

diagnostic hubs to

come to a future

21/2556 Chief executive's report

DP reported that the current focus is on patients that have been waiting for longer than 52 weeks. The majority of sites are back open with a few exceptions and good progress is being made in relation to the diagnostic hubs.

meeting
e staff.
of the
is not

64% of staff have so far received a vaccine with 74% of those being frontline staff. RGW asked about plans for vaccinating the remaining staff, particularly in light of the specific challenges the trust has with space. TL advised that the vaccine is not mandated so it is important to try to encourage those staff that are vaccine hesitant in order to increase uptake, and look at every option available.

Discussion took place about how the trust is now seeing patients. The board was advised that video consultation has been successful but some patients still require a face to face appointment, therefore the video consultation element needs to be built in to the pathway. As patients feel more confident about being out in public the desire for video consultation has diminished, so there is a clear need to reassure patients that the pathway is appropriate and safe. Ideally the trust wants to continue to drive a move to digitising the clinical pathway where it is both possible and clinically appropriate.

A full report on the staff survey will come to the next meeting but it was noted that 52% of staff responded to the staff survey. There are areas of positive engagement but clearly areas where improvement is required.

The trust took part in the day of reflection and remembrance on 23 March which recognised the important contribution made by staff to the system and other hospitals. TG offered condolences to the families of those staff that have sadly passed away and thanks to those staff that were redeployed.

The board delegated authority to Jonathan Wilson and Helen Essex to sign the ESCROW agreement which relates to the RPIF funding for UCL. The agreement is the mechanism by which funds will be held until draw down is required. JW advised that the funds would not be drawn down until the full business case has been approved.





21/2557 Oriel design engagement update

Work is currently taking place to challenge the assumptions made about what needs to be within the scope of the building. A clear plan is required that can inform the design team and in turn inform the FBC.

Work is also being done on internal interiors and wayfinding and making sure the design is appropriate for people with visual impairments, which includes a number of areas such as the atrium, acoustics and art strategy.

The team has also recommended the primary pedestrian route to the London Borough of Camden and reached agreement on the green line. Discussions are taking place with Camden and TfL to understand current and future bus provision.

Three weeks of testing has been done in relation to mock up space for consultation rooms, theatres, wet and dry labs. Users were shown the comparison between the current space available at City Road and what will be available in Oriel.

The design team has developed a template that ensures the space is flexible on each floor. The next stage is to lock down the decisions required about what needs to be in the building on Day One. It is acknowledged that there is a cost associated with additional flexibility but that this is likely to be the long term legacy of the building. However it will be difficult to pull back from the decisions made in the shorter term due to the cost impact. The clinical model and demand and capacity model are reviewed on a regular basis.

DH advised that the impact of this is that the stage 4 design will overlap with construction which presents a number of risks. There will be some key decisions to be made in the near future although it was stressed that if there are recommendations made that require a material change to assumptions made in the OBC assumptions they would need formal board approval.

21/2558 Freedom to speak up Q3 report

The FTSU guardians work across the network and provide a cultural safe space for people to raise concerns. Guardians are able to direct staff to the appropriate resource in order to assist them in resolving their concerns. The plan is to put in place FTSU champions across network sites.

A number of engagement events have been done with staff and approximately 50% of the concerns raised have been prompted by these events.

Wellbeing concerns have decreased over the last three quarters. Anecdotal feedback is that the wellbeing initiatives put in place are being well received. There have been no serious patient safety concerns but it is important to make sure the data is triangulated with information from incidents and the staff survey. IT advised that it is challenging to find themes but where a theme emerges then this would be addressed.





Discussion took place about how guardians can validate their effectiveness. Ideally this should be done through the staff survey which should show changes within the organisation that confirm their use as a conduit.

21/2559 Integrated performance report

The trust is still seeing restrictions in capacity in some areas. Cancer performance remains strong, partly due to the innovations put in place by the team.

Diagnostic standards are being achieved although there are patients waiting longer than the standard often due to patient choice. The majority of focus is on the longest-waiting patients and there is a clear trajectory to address 52-week waits by the end of Q1.

It is anticipated that there will be staffing improvements in inpatient. Divisions also need to focus on factors such as appraisal and IG compliance in the coming months. Extra resource is being put in place in order to respond to the increasing number of calls coming in to the trust. Teams are also looking to get proactive communication out to patients that have not been contacted for a time. The intention is to send letters out that provide clarity to specific groups of patients. Teams are reviewing patients that are included in the backlog and the specific messages that need to go out to each cohort.

21/2560 Finance report

The trust is currently showing a £1.6m surplus which is favourable to plan due to activity levels being below the block funding arrangement and significant pay and non-pay favourable variances.

Forecast outturn is £1.6m with accruals relating to annual leave and the elective incentive scheme impact.

Cash is at £81m and above forecast. The debt position has increased but ageing remains positive and there will be a further reduction before the end of the year. The 30-day debt position relates to both NHS and non-NHS. The position will be split out for further analysis at the finance committee.

In summary the trust is in a good position to exit the year although there are still a number of unknown upside variables. The NHS as a whole is seeing a particularly challenged financial position for the year. A national webinar will be held on 26 March to address how next year will operate.

21/2561 Report from the quality and safety committee

The committee received an infection control report and was assured about the positive relationship with UAE and liaison with the team about developing closer links with the trust in the area of clinical governance.





Areas of concern relate to vaccination and space as well as SLAs with host trusts. This area needs focus to make sure there is clear understanding as to the arrangements in place with those trusts.

Discussion also took place about the need for focus on communication with vulnerable patients and consultation on quality priorities.

20/2562 People and culture committee terms of reference

The committee reviewed ongoing objectives and context. Areas of assurance will focus on workforce transformation, education and training to support the workforce, oversight of HR processes/ER and which areas should come to the board and which can be dealt with by the committee.

The committee will continue to seek assurance as to whether workforce strategy objectives are correct and how delivery is progressing. There are a number of moving parts and it is critical to bring them together to make sure the workforce is fit for purpose for the future.

The committee will also review issues such as taking lessons from the staff survey and particular areas of concern such as EDI.

The committee terms of reference were approved.

21/2563 Identify any risk items arising from the agenda

No additional risks were identified.

21/2564 AOB

None.

21/2565 Date of the next meeting - Thursday 22 April 2021

BOARD ACTION LOG

Meeting Date	Item No.	Item	Action	Responsible	Due Date	Update/Comments	Status
25.02.21	20/2541	Matters arising and action points	TL to advise on a date for an update on leading and	TL	25.03.21		Closing
			guiding to come to the board.				
25.02.21	20/2550	Identify any items for the risk register arising	Issues around workforce and annual leave to be	HE	22.04.21		Closing
		from the agenda	incorporated into the recovery risk				
25.03.21	20/2555	Matters arising and action points	Full update on leading and guiding group to be provided	TL	22.04.21		Open
			at the April meeting				
25.03.21	20/2556	Chief Executive's Report	Full report on diagnostic hubs to come to a future	JS	1 Jul 2021		Open
			meeting				





Glossary of terms – April 2021				
Oriel	A project that involves Moorfields Eye Hospital NHS Foundation Trust and its research partner, the UCL Institute of Ophthalmology, along with Moorfields Eye			
	Charity working together to improve patient experience by exploring a move from			
	our current buildings on City Road to a preferred site in the Kings Cross area by			
	2023.			
AAR	After action review			
AfL	Agreement for lease			
AHP	Allied health professional			
Al	Artificial intelligence			
ALB	Arms length body			
AMRC	Association of medical research charities			
ASI	Acute slot issue			
BAF	Board assurance framework			
BAME	Black, Asian and minority ethnic			
BRC	Biomedical research centre			
CCG	Clinical commissioning group			
CIP	Cost improvement programme			
CQC	Care quality commission			
CSSD	Central sterile services department			
DHCC	Dubai Healthcare City			
DSP	Data security protection [toolkit]			
ECLO	Eye clinic liaison officer			
EDI	Equality diversity and inclusivity			
EDHR	Equality diversity and human rights			
EIS	Elective incentive scheme			
EMR	Electronic medical record			
ENP	Emergency nurse practitioner			
EU	European union			
FBC	Full business case			
FFT	Friends and family test			
FT	Foundation trust			
FTSUG	Freedom to speak up guardian			
GDPR	General data protection regulations			
GIRFT	Getting it right first time			
GMC	General medical council			
GoSW	Guardian of safe working			
HCA	Healthcare assistant			
I&E	Income and expenditure			
ICS	Integrated care system			
IOL	Intra ocular lens			
IPR	Integrated performance report			
ITU	Intensive therapy unit			
JDV	Joint development vehicle			





KPI	Key performance indicators
LCFS	Local counter fraud service
LD	
MEH	Learning disability
	Moorfields Eye Hospital National audit office
NAO	
NCL NUCL/E	North Central London
NHSI/E	NHS Improvement/England
NIHR	National institute for health research
NMC	Nursing & midwifery council
OBC	Outline business case
OD	Organisation development
PALS	Patient advice and liaison service
PAS	Patient administration system
PbR	Payment by results
PDC	Public dividend capital
PID	Patient identifiable data
PP	Private patients
PPE	Personal protective equipment
QIA	Quality impact assessment
QIPP	Quality, innovation, productivity and prevention
QRA	Quantitative risk assessment
QSC	Quality & safety committee
QSIS	Quality service improvement and sustainability
RAG	Red amber green [ratings]
RCA	Root cause analysis
R&D	Research & development
RTT	Referral to treatment
SCC	Strategy & commercial committee
SGH	St Georges University Hospital
SI	Serious Incident
SLA	Service level agreement
ST	Senior trainee
STP	Sustainability and transformation partnership
UAE	United Arab Emirates
UCL	University College London
UCLH	University College London Hospital
VFM	Value for money
VR	Vitreo-retinal
WDES	Workforce disability equality standards
WRES	Workforce race equality standards
YTD	Year to date





Agenda item 05 Chief executive's report Board of directors 22 April 2021

Chief Executive's report

I would like to provide continued assurance to the board about the Trust response to the COVID-19 pandemic.

Operational Response to the COVID-19 second wave

In response to the low prevalence of Covid-19 in the London region and the national incident level of the NHS Covid-19 response reducing from level 4 to level 3, Moorfields has shifted focus onto recovering clinical services in as timely and safe a manner as possible. Activity levels have increased in March and excellent progress has been made booking the longest waiting patients in for treatment. The Trust is significantly ahead of the plan that it set to treat patients who have waited over 52 weeks for their treatment and is expecting to treat the majority of these patients by the end of May rather than the end of June as was reported at the last Trust Board.

Actions remain in place to manage the safety of the trust environment during the Covid-19 pandemic and some of these, such as the need to ensure social distancing, will continue to provide an operational challenge for Moorfields as we seek to deliver previous levels of activity. It is recognised that staff have worked exceptionally hard to help the Trust respond to the latest wave of the pandemic and it has therefore been essential that they are able to take some annual leave before they help the trust to focus fully on recovery.

Moorfields is liaising with partners in the North Central London ICS to ensure that our recovery plans are supportive of those of the wider region. We have continued to offer mutual aid to surrounding organisations, however it is anticipated that we may need to play a much larger role in this area when we have treated all of our patients who have waited over 18 weeks in the second half of the new financial year.

Managing the patient backlog within services

As a result of the pandemic and the intermittent closure of clinical services over the past 12 months, it is acknowledged that there are significantly more patients currently waiting for diagnosis and treatment than there would normally be. Operational and clinical colleagues are assessing the backlog of patients on a daily basis to ensure that patients are booked according to clinically-led risk stratification tools which balance a number of criteria including their clinical prioritisation, date on which patients were referred and other relevant factors such as social economic background.

A new forum is being established between the Trust Executive Directors and the Service / Divisional Directors to ensure that available capacity is balanced appropriately between clinical teams, and that innovative approaches to delivering patient care are considered and enacted in an accelerated manner. This group will also ensure that communication with patients on their diagnosis and treatment is clear and concise, and that the Trust's short term investment decisions will be maximised to help clear the backlog of patients as quickly as possible.

As the trust continues to recover its activity, work is underway to liaise with patients who are currently waiting for an appointment. In addition to the reviews by the sub specialties, the trust has also made contact with patients who may have additional vulnerabilities such learning disabilities or dementia offering them reassurance and the opportunity to contact the trust if they had concerns. The safeguarding team have also been available to talk to patients if required.

Staff Covid Vaccinations

The trust has now vaccinated 77% of the total workforce (73% of frontline staff) and continues to offer weekly vaccination clinics for staff yet to be vaccinated. The vaccination champions continue to offer support and advice for staff.

Strategy refresh

There are two parallel processes taking place in respect of the strategy refresh. The first is that, following the Board strategy away day, a series of executive-led task and finish groups are to be held in April/May. These will take the Board discussions as a starting point to work up some more specific strategic objectives for 2021-26. These objectives are likely to speak to the following themes:

Outcomes:

- Patient outcomes (unwarranted variation in outcomes, equity and productivity)
- Patient experience (a sector-leading approach to how patients experience care)
- Leadership (in specialty and system)
- Value (shape of the network and cost management)

Enablers:

- Digital (architecture, data and user experience)
- Research (big data, AI, science and service innovations)
- Workforce and education (our role in shaping and training the future workforce)

A group is to meet for each area, tasked with bringing back to the Board a suggested strategic objective, along with an indication of measures, resources and risks. Thereafter the next stage will be prioritisation of said objectives before proposals are then brought for forward reporting and monitoring.

The second process is the staff and patient engagement work, which will inform the work of the task and finish groups as far as possible. So far this has comprised a series of interviews with key internal staff, and a staff survey. We have had over 200 responses to the survey, the headline messages being broadly consistent with the direction of travel identified by the Board. The next stage of engagement is a patient story exercise, and finally, some workshops, scheduled for mid-May. These outputs will be used as a check on our thinking before the strategy is finalised and will provide invaluable insights to shape the specifics of the strategic work programmes supporting delivery.

System and partnership working

System facing work continues to focus on the following three areas:

- 1. Systemic responses to Covid recovery, with a particular focus on addressing long term waits.
- 2. How this positive collaboration might be formalised longer term in the context of Integrated Care Systems, provider collaboratives and clinical networks. Moorfields has put a proposal to NHS London in this regard.
- 3. Contributing to the national eye care programme and NHSX work, variously on the primary care interface and use of diagnostic hubs.

Oriel update

The communications and engagement programme for Oriel during the spring and summer is focused on paving the way for the new centre, gathering feedback on aspects of the interior design, and proactively maintaining positive relationships with key stakeholders, targeting staff and patients in particular. We have implemented a 'two-tier' approach to our engagement, which initially involves generally raising awareness of the proposals for a new, integrated centre at the St Pancras Hospital site and promoting the benefits of moving to a fit-for-purpose building. The second component is a 'deeper dive' into the key themes that resonate with our audience groups, based on the principles of co-design. This will culminate in an Oriel summer showcase that encapsulates our discussions and demonstrates how feedback from a wide range of user perspectives, including the sight loss community, has been incorporated into the evolution of the building's design.

People and awards

Four colleagues have been recognised in a list of the most influential women in the world of ophthalmology. The **Ophthalmologist Power List** honours clinicians, scientists and engineers who have made a significant contribution to their field. The 2021 list, for the first time, features only women.

Each nomination celebrates an individual who has made a lasting impact on the field, whether that is through a philanthropic initiative or their ongoing commitment to innovation. This year saw 1,200 nominations for over 300 women working in ophthalmology across the world. Congratulations to our extraordinary Moorfields' clinicians who feature on The Power List 2021: Professor Mariya Moosajee, consultant ophthalmologist, Dawn Sim, consultant ophthalmic surgeon, Professor Sobha Sivaprasad, consultant ophthalmologist and Louisa Wickham, medical director.

Professor Frank Larkin, consultant ophthalmic surgeon, has been appointed editor-in-chief of the **British Journal of Ophthalmology (BJO).** The BJO is an international peer-reviewed journal for ophthalmologists and visual science specialists and is the leading ophthalmology journal outside the United States. Frank's ambition is to further expand the quality and standing of the BJO, building on the previous editors' stewardship and I would like to congratulate him on behalf of the board on this prestigious appointment.

This month we say farewell to Chris Canning, who is stepping down from his role as **chief clinical information officer**. I would like to thank Chris on behalf of the board for the exceptional leadership he has shown in this area and wish him every success for the future. I am pleased to confirm that the trust has appointed Pete Thomas as the chief clinical informatics officer and he has been invited to a future board meeting to share his vision for the new department of digital medicine, a particularly exciting development for the trust.

Moorfields has recently elected new governors to its **membership council**. This year the trust received the highest number of nominations ever, with 64 nominations to fill seven seats.

We welcome our new governors:

- Vijay Arora (north west London public constituency)
- Marcy Ferrer (patient constituency)
- Vijay Tailor (staff governor for the City Road constituency)

The following governors were re-elected:

- Richard Collins (north east London and Essex constituency (previously a governor in the patient constituency)
- Rob Jones (patient constituency)
- Paul Murphy (north central London constituency)
- Naga Subramanian (south east London constituency)

We also say goodbye to three governors – Manzur Ahmed, Ella Preston and Brian Watkins – and I would like to join the chairman in formally thanking them for their hard work and the positive contribution they have each made to Moorfields in their respective governor roles.

Financial position

At the time of writing the March and year-end position is being finalised as per national timelines and this paper will be updated accordingly in advance of the Board.

David Probert, chief executive April 2021





Moorfields Eye Hospital NHS Foundation Trust

2020 NHS Staff Survey

Summary Benchmark Report

Organisation details



Moorfields Eye Hospital NHS Foundation Trust

2020 NHS Staff Survey



Organisation details

Completed questionnaires 1,184

2020 response rate 54%

See response rate trend for the last 5 years

Survey details

Survey mode Online

Sample type Census

This organisation is benchmarked against:

Acute Specialist Trusts



2020 benchmarking group details

Organisations in group: 14

Median response rate: 56%

No. of completed questionnaires:

17,827

Using the report



Key features

Ouestion number and text (or the theme) specified at the top of each slide

Question-level results are always reported as percentages; the **meaning** of the value is outlined along the axis. Themes are always on a 0-10pt scale where 10 is the best score attainable

> **Colour coding** highlights best / worst results, making it easy to spot questions where a lower percentage is better – in such instances 'Best' is the bottom line in the table

Keep an eye out!

Number of responses for the organisation for the given question



'Best', 'Average', and 'Worst' refer to the benchmarking group's best, average and worst results



Worst

100

90

70

60

50

2019

19.0%

18.0%

12.1%

2020

24.1%

15.8%

16.8%

13.3%

% of staff saying they experienced at least one incident of bullying, harassment or abuse

Full details on how the scores are calculated are provided in the Technical **Document**, under the Supporting Documents section of our results page

Survey Coordination Centre




Theme results

The calculation for the immediate managers theme has changed this year due to the omission of one of the questions which previously contributed to the theme. This change has been applied retrospectively so data for 2016-2020 shown in the charts are comparable for this theme, however these figures are not directly comparable to the results reported in previous years. For more details please see the <u>technical document</u>.

Moorfields Eye Hospital NHS Foundation Trust 2020 NHS Staff Survey Results







Survey Coordination Centre




Theme results – Trends

Moorfields Eye Hospital NHS Foundation Trust 2020 NHS Staff Survey Results






































































Survey Coordination Centre



Theme results – Covid-19 classification breakdowns

Moorfields Eye Hospital NHS Foundation Trust 2020 NHS Staff Survey Results

Covid-19 classification breakdowns



Covid-19 questions

Staff were asked four classification questions relating to their experience during the Covid-19 pandemic:

a.	Have you worked on a Covid-19 specific ward or area at any time?	Yes	☐ No
b.	Have you been redeployed due to the Covid-19 pandemic at any time?	Yes	☐ No
C.	Have you been required to work remotely/from home due to the Covid-19 pandemic?	Yes	☐ No
d.	Have you been shielding? Yes, for myself Yes, for a member of my ho	usehold	☐ No

The charts on the following pages show the breakdown of theme scores for staff answering 'yes' to each of these questions, compared with the results for all staff at your organisation. Results are presented in the context of the highest, average and lowest scores for similar organisations.

Comparing your data

To improve overall comparability, the data have been weighted to match the occupation group profile of staff at your organisation to that of the benchmarking group, as in previous charts. However, there may be differences in the occupation group profiles of the individual COVID-19 subgroups. For example, the mix of occupational groups across redeployed staff at your organisation may differ from similar organisations. This difference would not be accounted for by the weighting and therefore may affect the comparability of results. As such, a degree of caution is advised when interpreting your results.

Further information


Results for these groups of staff, including data for individual questions, are also available via the <u>online dashboards</u>. Please note that results presented in these dashboards have not been weighted where no benchmarking takes place and so may vary slightly from those shown in this report.






2020 NHS Staff Survey Results > Theme results - Covid-19 classification breakdowns > Equality, diversity & inclusion




































2020 NHS Staff Survey Results > Theme results - Covid-19 classification breakdowns > Safe environment - Bullying & harassment





































Theme results – Detailed information






014

Does your organisation act fairly with regard to career progression / promotion, regardless of ethnic background, gender, religion, sexual orientation, disability or age?




Q15a

In the last 12 months have you personally experienced discrimination at work from patients / service users, their relatives or other members of the public?



Q15bIn the last 12 months have you personally experienced discrimination at work from manager / team


leader or other colleagues?







Q26b
Has your employer made adequate adjustment(s) to enable you to carry out your work?








Q5hThe opportunities for flexible working patterns



Q11aDoes your organisation take positive action on health and well-being?



Q11b
In the last 12 months have you experienced musculoskeletal problems (MSK) as a result of work activities?








Q11cDuring the last 12 months have you felt unwell as a result of work related stress?

Q11dIn the last three months have you ever come to work despite not feeling well enough to perform your duties?









Q5bThe support I get from my immediate manager



Q8cMy immediate manager gives me clear feedback on my work



Q8dMy immediate manager asks for my opinion before making decisions that affect my work







Q8g

My immediate manager values my work

Q8fMy immediate manager takes a positive interest in my health and well-being

80 85 % of staff selecting 'Agree'/'Strongly Agree' % of staff selecting 'Agree'/'Strongly Agree' 75 80 70 75 65 70 60 65 55 60 2016 2018 2020 2016 2020 2017 2019 2017 2018 2019 **Best** 73.6% 74.1% 77.0% **Best** 77.7% 77.2% 79.9% 77.6% 75.6% 80.2% 78.6% 73.0% 72.3% 71.4% 67.7% 72.4% Your org 76.5% 75.7% 75.9% 73.3% 73.8% Your org **Average** 69.7% 69.3% 72.2% 72.4% 74.3% **Average** 73.4% 73.0% 75.3% 75.1% 76.0% 59.3% 64.1% 65.3% 66.9% 69.5% 64.9% 69.1% 69.8% 70.8% 69.5% Worst Worst







Q4c
I am involved in deciding on changes introduced that affect my work area / team / department

70 % of staff selecting 'Agree'/'Strongly Agree' 65 60 55 50 45 2016 2017 2018 2019 2020 66.0% 64.6% 62.1% 62.6% 58.7% **Best** 55.9% 50.2% 53.4% 51.7% 50.3% Your org **Average** 55.8% 56.3% 58.0% 57.7% 54.9% 48.1% 50.2% 49.9% 50.0% 49.2% Worst

Q4jI receive the respect I deserve from my colleagues at work



Q6aI have unrealistic time pressures








Q6b Q8a Q6c I have a choice in deciding My immediate manager Relationships at work are strained how to do my work encourages me at work 65 60 80 of staff selecting 'Agree'/'Strongly Agree' % of staff selecting 'Often'/'Always' 55 of staff selecting 'Never'/'Rarely' 60 75 50 55 45 70 50 % 40 % 45 35 65 2018 2020 2018 2020 2018 2020 2019 2019 2019 **Best** 63.7% 62.0% 62.9% **Best** 54.9% 55.6% **Best** 78.5% 76.6% 55.5% 77.2% 53.9% 49.6% 49.1% 44.6% 44.5% 46.8% 70.8% 70.8% 72.6% Your org Your org Your org **Average** 57.3% 58.3% 58.0% **Average** 49.2% 48.4% 49.1% 71.5% 72.5% 73.2% Average 51.6% 49.6% 49.1% 39.8% 45.6% 67.2% 70.8% 69.1% Worst Worst 39.6% Worst







Q19aI often think about leaving this organisation



Q19bI will probably look for a job at a new organisation in the next 12 months



Q19cAs soon as I can find another job, I will leave this organisation








Q7aI am satisfied with the quality of care I give to patients / service users

95 % of staff selecting 'Agree'/'Strongly Agree' 90 85 80 75 2016 2017 2018 2019 2020 93.0% 92.9% 91.4% 91.3% 92.3% **Best** 91.8% 88.6% 87.9% 87.8% 88.4% Your org **Average** 87.3% 87.7% 88.3% 88.3% 88.4% 75.1% 80.8% 82.7% 80.8% 84.4% Worst

Q7bI feel that my role makes a difference to patients / service users



Q7cI am able to deliver the care I aspire to









O13a

In the last 12 months how many times have you personally experienced harassment, bullying or abuse at work from patients / service users, their relatives or other members of the public?




Q13b

In the last 12 months how many times have you personally experienced harassment, bullying or abuse at work from managers?



Q13c
In the last 12 months how many times have you personally experienced harassment, bullying or abuse at work from other colleagues?









O12a

In the last 12 months how many times have you personally experienced physical violence at work from patients / service users, their relatives or other members of the public?




Q12b In the last 12 months how many times have you personally experienced physical violence at work from managers?



one incident of violence

Q12c In the last 12 months how many times have you personally experienced physical violence at work from other colleagues?



one incident of violence







Q16aMy organisation treats staff who are involved in an error, near miss or incident fairly



Q16cWhen errors, near misses or incidents are reported, my organisation takes action to ensure that they do not happen again



Q16dWe are given feedback about changes made in response to reported errors, near misses and incidents









Q17bI would feel secure raising concerns about unsafe clinical practice



Q17c
I am confident that my organisation would address my concern




Q18bMy organisation acts on concerns raised by patients / service users







Q2aI look forward to going to work



Q2bI am enthusiastic about my job



Q2cTime passes quickly when I am working








Q4aThere are frequent opportunities for me to show initiative in my role



Q4bI am able to make suggestions to improve the work of my team / department



Q4dI am able to make improvements happen in my area of work











Q18a Care of patients / service users is my organisation's top priority



Q18c I would recommend my organisation as a place to work



Q18d If a friend or relative needed treatment I would be happy with the standard of care provided by this organisation







Q4hThe team I work in has a set of shared objectives

Q4iThe team I work in often meets to discuss the team's effectiveness





Workforce Equality Standards

Workforce Equality Standards



This section contains data required for the NHS Staff Survey indicators used in the Workforce Race Equality Standard (WRES) and Workforce Disability Equality Standard (WDES). Data presented in this section are unweighted.

Full details of how the data are calculated are included in the Technical Document, available to download from our results website.

Workforce Race Equality Standard (WRES)

This contains data for each organisation required for the NHS Staff Survey indicators used in the Workforce Race Equality Standard (WRES). It includes the 2017, 2018 and 2019 trust/CCG and benchmarking group median results for q13a, q13b&c combined, q14, and q15b split by ethnicity (by white / BME staff).

Workforce Disability Equality Standard (WDES)

- This contains data for each organisation required for the NHS Staff Survey indicators used in the Workforce Disability Equality Standard (WDES). It includes the 2018 and 2019 trust/CCG and benchmarking group median results for q5f, q11e, q13a-d, and q14 split by staff with a long lasting health condition or illness compared to staff without a long lasting health condition or illness. It also shows results for q26b (for staff with a long lasting health condition or illness only), and the staff engagement score for staff with a long lasting health condition or illness and the overall engagement score for the organisation.
- The WDES breakdowns are based on the responses to q26a *Do you have any physical or mental health conditions or illnesses lasting or expected to last for 12 months or more?* In 2020, the question text was shortened and the word 'disabilities' was removed but the question and WDES results still remain historically comparable.




Workforce Race Equality Standard (WRES)











2020 NHS Staff Survey Results > WRES > Percentage of staff experiencing harassment, bullying or abuse from staff in last 12 months




100 90 Percentage of staff experiencing harassment, bullying or abuse from staff in last 12 months 80 70 60 50 40 30 20 10 0 2017 2018 2019 2020 White: Your org 25.3% 26.9% 27.4% 24.9% **BME: Your org** 30.4% 27.7% 28.5% 31.5% 25.1% **White: Average** 22.5% 23.2% 21.6% **BME: Average** 25.3% 27.3% 29.4% 28.7% **White: Responses** 464 503 527 521 **BME: Responses** 540 447 582 603 Average calculated as the median for the benchmark group












2020 NHS Staff Survey Results > WRES > Percentage of staff experienced discrimination at work from manager / team leader or other colleagues in last 12 months







Workforce Disability Equality Standard (WDES)


The approach to calculating the benchmark median scores and the way in which the data for Q13d are reported has changed this year. These changes have been applied retrospectively so historical data shown in the average calculations and all figures for Q13d are comparable. However, these figures are not directly comparable to the results reported in previous years. For more details please see the <u>technical document</u>.







Percentage of staff experiencing harassment, bullying or abuse from patients, relatives or the public in last 12 months



Staff with a LTC or illness: Your org Staff without a LTC or illness: Your org Staff with a LTC or illness: Average Staff without a LTC or illness: Average Staff with a LTC or illness: Responses **Staff without a LTC or illness: Responses** 784 1,001 998


Average calculated as the median for the benchmark group



2020 NHS Staff Survey Results > WDES > Percentage of staff experiencing harassment, bullying or abuse from manager in last 12 months



harassment, bullying or abuse from manager in last 12 months Percentage of staff experiencing



Staff with a LTC or illness: Your org Staff without a LTC or illness: Your org Staff with a LTC or illness: Average Staff without a LTC or illness: Average Staff with a LTC or illness: Responses **Staff without a LTC or illness: Responses** 764 995


Average calculated as the median for the benchmark group







Percentage of staff experiencing harassment, bullying or abuse from other colleagues in last 12 months




Staff with a LTC or illness: Average Staff without a LTC or illness: Average Staff with a LTC or illness: Responses **Staff without a LTC or illness: Responses** 767 1,000 996 Average calculated as the median for the benchmark group







harassment, bullying or abuse at work, they or a colleague reported Percentage of staff saying that the last time they experienced



Staff without a LTC or illness: Your org Staff with a LTC or illness: Average Staff without a LTC or illness: Average Staff with a LTC or illness: Responses **Staff without a LTC or illness: Responses** 241 345 357


Average calculated as the median for the benchmark group







Percentage of staff who believe that their organisation provides equal opportunities for career progression or promotion




Staff with a LTC or illness: Your org Staff without a LTC or illness: Your org Staff with a LTC or illness: Average Staff without a LTC or illness: Average Staff with a LTC or illness: Responses **Staff without a LTC or illness: Responses** 527 677 663







come to work, despite not feeling well enough to perform their duties Percentage of staff who have felt pressure from their manager to











Percentage of staff satisfied with organisation values their work the extent to which their










adjustment(s) to enable them to carry out Percentage of staff with a long lasting health condition or illness saying their employer has made adequate their work








Staff engagement score (0-10)

Organisation average

Organisation Responses



Survey Coordination Centre



Appendices

Moorfields Eye Hospital NHS Foundation Trust 2020 NHS Staff Survey Results Survey Coordination Centre




Appendix A: Response rate

Moorfields Eye Hospital NHS Foundation Trust 2020 NHS Staff Survey Results








Survey Coordination Centre



Appendix B: Significance testing - 2019 v 2020 theme results

Moorfields Eye Hospital NHS Foundation Trust 2020 NHS Staff Survey Results







The table below presents the results of significance testing conducted on this year's theme scores and those from last year*. It details the organisation's theme scores for both years and the number of responses each of these are based on.

The final column contains the outcome of the significance testing: ↑ indicates that the 2020 score is significantly higher than last year's, whereas ↓ indicates that the 2020 score is significantly lower. If there is no statistically significant difference, you will see 'Not significant'. When there is no comparable data from the past survey year, you will see 'N/A'.

Theme	2019 score	2019 respondents	2020 score	2020 respondents	Statistically significant change?
Equality, diversity & inclusion	8.6	1175	8.4	1170	Not significant
Health & wellbeing	6.0	1180	6.1	1173	Not significant
Immediate managers †	6.8	1186	6.9	1182	Not significant
Morale	6.0	1154	6.2	1175	Not significant
Quality of care	8.0	1075	8.0	1065	Not significant
Safe environment - Bullying & harassment	7.8	1160	7.7	1172	Not significant
Safe environment - Violence	9.8	1168	9.8	1172	Not significant
Safety culture	7.0	1167	7.0	1181	Not significant
Staff engagement	7.4	1196	7.4	1182	Not significant
Team working	6.5	1187	6.7	1162	Not significant

^{*} Statistical significance is tested using a two-tailed t-test with a 95% level of confidence.

[†] The calculation for the immediate managers theme has changed this year due to the omission of one of the questions which previously contributed to the theme. This change has been applied retrospectively so data for 2016-2020 shown in this table are comparable. However, these figures are not directly comparable to the results reported in previous years. For more details please see the <u>technical document</u>.





Agenda item 07
Learning from deaths
Board of directors 22 April 2021





Report title	Learning from deaths
Report from	Louisa Wickham, medical director
Prepared by	Julie Nott, head of risk & safety
Link to strategic objectives	We will pioneer patient-centred care with exceptional clinical outcomes and excellent patient experience

Executive summary

This report provides an update regarding how we learn from deaths that occur within Moorfields defined by criteria (see Annex below) as set out in trust policy. It is a requirement for all trusts to have a similar policy.

The trust has identified 0 patient deaths in Q4 that fall within the scope of the learning from deaths policy. The investigation into the death of the patient that occurred during Q3 remains on-going. The Inquest in relation to this death was held on 12 April 2021.

Quality implications

The board needs to be assured that the trust is able to learn lessons from serious incidents in order to prevent repeat mistakes and minimise patient harm.

Financial implications

Provision of the medical examiner role for Moorfields may have cost implications for the organisation.

Risk implications

If the trust fails to learn from deaths there is clinical risk in relation to our ability to provide safe care to patients, reputational risk, financial risk of potential litigation and legal risk to directors.

Action Required/Recommendation

The board is asked to receive the report for assurance and information.

For Assurance	✓	For decision	For discussion	To note	✓

Learning from deaths Board paper

This report satisfies the requirement to provide the trust board with an update regarding compliance with, and learning from, the NHS Improvement learning from deaths agenda.

The Q4 2020/21 data, as at 12 April 2021, is shown in table 1 below.

Indicator	Q1 2020/21	Q2 2020/21	Q3 2020/21	Q4 2020/21
Summary Hospital Mortality Indicator (as reported in the IPR)	0	0	0	0
Number of deaths that fall within the scope of the learning from deaths policy (see annex 1)	0	0	1	0
% of cases reviewed under the structured judgement review (SJR) methodology/ reviewed by the Serious Incident panel	N/A	N/A	100	N/A
Deaths considered likely to have been avoidable	N/A	N/A	0*	N/A

Table 1

Learning and improvement opportunities identified during Q4

• The Inquest into the death of the patient in Q3 2020/21 was held on 12 April 2021. HM Coroner returned a narrative verdict, concluding that the patient's death was, on the balance of probabilities, caused by an air embolus following the operation (endoresection of a choroidal melanoma) and/or operative treatment. A Prevention of Future Deaths (PFD) report is to be issued to the trust and a formal response to HM Coroner will be required. The SI investigation report will be concluded during Q1 2021/22 and will be reflective of the postmortem and Inquest findings and take account of any queries raised by the family of the deceased. It is anticipated that the learning from this case will be shared internationally.

Medical examiner role (update)

Medical Examiner support, in relation to deaths of admitted patients occurring on site at City Road, has been confirmed by UCLH. The provision of this service for Moorfields remains under development. It is hoped that this will be finalised and incorporated within relevant trust documents by the end of May/early June 2021.

Two national medical examiner update publications have been released by NHS Improvement since the Q3 report:

February 2021 https://www.england.nhs.uk/wp-content/uploads/2021/02/nme-bulletin-february-2021.pdf

^{**}pending completion of the SI investigation

Annex 1

Included within the scope of this Policy:

- All in-patient deaths;
- Patients who die within 30 days of discharge from inpatient services (where the Trust becomes aware of the death);
- Mandated patient groups identified by the NQB Learning from Deaths guidance including individuals with a learning disability, mental health needs or an infant or child;
- The death of any patient who is transferred from a Moorfields site and who dies following admission to another provider hospital;
- The death of any patient, of which the trust is made aware, within 48 hours of surgery;
- All deaths where bereaved families and carers, or staff, have raised a significant concern about the quality of care provision by Moorfields;
- Deaths of which the trust becomes aware following notification, and a request for information, by HM Coroner;
- Persons who sustain injury as a result of an accident (e.g. a fall down stairs) whilst on Trust premises and who subsequently die;
- Individual deaths identified by the Medical Examiner or through incident reporting or complaints or as a result of the Inquest process;

Excluded from the scope of this Policy:

 People who are not patients who become unwell whilst on trust premises and subsequently die;





Agenda item 08
Fit and proper person's report
Board of directors 22 April 2021

Report title	Fit and proper persons annual assurance report
Report from	Tessa Green, chairman
Prepared by	Company secretary on behalf of the director of workforce & OD
Link to strategic objectives	We will attract, retain and develop great people

Executive summary

The Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 requires all trusts to ensure that all executive and non-executive director posts (or anyone performing similar or equivalent functions) are filled by people that meet the requirements of the Fit and Proper Person Regulations (FPPR). The definition of directors includes those in permanent, interim or associate roles, irrespective of their voting rights.

The regulations place a duty on trusts to ensure that their directors are compliant with the FPPR and this report provides assurance to the board on this matter.

Due diligence checks have been undertaken and personal files reviewed by the company secretary and director of workforce & OD. Bankruptcy register and disqualified director register checks have been completed. All Board members are asked to confirm on an annual basis that they remain fit and proper to undertake their role.

A summary of action taken in the past year, learning from the annual review and further expected guidance is included for reference.

Quality implications

There is an expectation on senior leaders to set the tone and culture of the organisation, which has a direct impact on the quality of staff and patient experience.

Financial implications

There are no direct financial implications arising from this paper.

Risk implications

Application and review of the requirement minimises the opportunity for individuals to act in a manner that may be detrimental to patients, staff or the organisation as a whole whilst in a position of power and influence.

Action required/recommendation.

The board is asked to receive the report and take assurance from it.

1. Background

Under the requirements, the trust must not appoint to a post under the scope of the Regulated Activity Regulations without first satisfying itself that the individual:

- Is of good character
- o Has the necessary qualifications, competence, skills and experience
- Has the appropriate level of physical and mental fitness
- Has not been party to any serious misconduct or mismanagement (whether unlawful or not) in the course of carrying out a regulated activity
- o Is not deemed unfit under the Regulated Activities Regulations provisions
- Can provide the personal information as set out in the regulations which must be available to be supplied to the CQC when required.

These requirements must be held at the point of commencing the role and on an ongoing basis.

The CQC's definition of 'good character' is not the objective test of having no criminal convictions but rather a judgement to be made as to whether a person's character is such that they can be relied upon to do the right thing under all circumstances. The Trust will use its discretion in reaching a decision regarding character.

In the event that an individual ceases to be a fit and proper person, the individual may be summarily dismissed and the Trust will notify the individual and the trust's regulator.

The roles and responsibilities of individuals in relation to these guidelines are as follows:

- Trust Chair to take overall responsibility and accountability for ensuring all those required to confirm that they meet the requirements of the Regulated Activity Regulations do so at appointment and as an ongoing requirement
- Those within the scope of FPPR to hold and maintain suitability for the role they are undertaking,
 to respond to any requests for evidence of their ongoing suitability, to disclose any issues which may
 call into question their suitability for the role they are undertaking
- HR Department to undertake all recruitment checks for employees (including executive directors) and ensure the results are recorded and evidenced within an individual's file.
- Company secretary to undertake all appointment checks for non-executive directors and specific register checks for executive directors, and ensure the results are recorded and evidenced within an individual's file. To undertake an annual refresh of suitability for all board members.
- Agency providers to ensure the necessary checks have been outlined in this policy and make those
 checks available as and when required.

Compliance at the point of recruitment

The trust has in place robust processes with regard to the appointment of directors. These processes include the following:

- Confirming the status of the specific qualifications as outlined within the relevant JD/Person Spec and status of qualifications listed on an individual's CV
- Identity checks
- Qualification and registration checks
- Right to work checks
- o DBS checks
- References covering at least three years of employment, one of which must be from the most current/recent employer

- o Search of insolvency/bankruptcy register and disqualified directors register
- Review of full employment history seeking an explanation of any gaps in employment
- Health questionnaire and occupational health clearance
- A search of the individual through internet search engines to note any information in the public domain which the trust should be made aware of
- A self-declaration from the individual
- An explicit clause within the contract of employment to ensure the individuals accept the requirements of the Regulated Activity Regulations at the point they commence with the trust

Assessment of continued compliance

The trust is responsible for ensuring the continued compliance of those persons to whom the Regulated Activity Regulations apply. This requirement is fulfilled through a number of processes including:

- o The completion of an annual self-declaration by all directors
- o Annual checks for credit, bankruptcy, disqualification and regulation
- o Formal appraisal processes
- o Maintenance of the register of declared interests

Continued compliance is the responsibility of the company secretary with the exception of the formal appraisal process which is the responsibility of the line manager.

2. Annual review

The due diligence process has been undertaken in line with previous years as follows:

- Each Director has been asked to sign a annual declaration covering the specific aspects of the FPPR;
- New appointees to the Board of Directors have been through this process prior to appointment (this
 year, new appointees are the chief operating officer, medical director and one new non-executive
 director).
- Annual appraisals are in place. The chief executive appraises the executive directors; the senior
 independent director appraises the chair; the chair appraises the non-executive directors; the relevant
 director appraises anyone who acts as a director or board member but does not report directly to the
 chief executive.
- Performance reviews for the non-executive directors are all scheduled to be completed by 1 May 2021 and will be reported to the governor remuneration and nominations committee.
- The outcome of the executive performance reviews were reported to the board remuneration committee on 24 September 2020.
- All director contracts include the necessary FPPR statement.
- Each personal file has been checked by the company secretary and director of workforce and OD.
- Disqualified Directors and insolvency checks have been undertaken and evidenced, as well as professional registration checks.
- The register of declared interests is updated at least annually and directors inform the company secretary when their declarations change.

3. This year's learning

As in the previous year, the trust has found that there can be complications arising from appointments where individuals are unable to attend the trust in person to provide identity documents (due to the Covid-19 pandemic) but the separate verification process put in place in 2020 has addressed this issue.

Moonfields Eye - ospital <u>Mulliples (Minister</u>

4. Further guidance

In July 2018, Tom Kark QC was commissioned to review the scope, operation and purpose of the Fit and Proper Person Test (FPPT). The review looked in particular at how effective the FPPT is in preventing unsuitable staff from being redeployed or re-employed in the NHS and follows the Kirkup report into Liverpool Community Health Trust in February 2018.

The Kark Review identified a range of problems with the FPPT and made the following recommendations:

- All directors should meet specified standards of competence to sit on the board of any health providing organisation
- 2. A central database should be created, holding relevant information about qualifications and history about each director (including NEDs)
- 3. Full, honest and accurate mandatory employment references should be required from any relevant employer where an employee is moving from a post covered by Regulation 5 to a post covered by Regulation 5
- 4. The FPPT should be extended to all commissioners and other appropriate ALBs
- 5. An organisation should be set up with the power to suspend and disbar directors who are found to have committed serious misconduct
- 6. Further work is done to examine how the test works in the context of the provision of social care.

The government accepted recommendations one and two: redefining the criteria used in the FPPT and the creation of a central database for NHS board level directors.

However, it was indicated that even implementing the first two recommendations would stretch beyond the summer of 2019 and there has been no significant update as to potential next steps. Trusts currently await further guidance on whether any changes are likely to be made.



Report to Trust Board						
Report Title	Integrated Performance Report - March 2021					
Report from	Jon Spencer - Chief Operating Officer					
Prepared by	Performance And Information Department					
Previously discussed at						
Attachments						

Brief Summary of Report

The Integrated Performance Report highlights a series of metrics regarded as Key Indicators of Trust Performance and cover a variety of organisational activities within Operations, Quality and Safety, Workforce, Finance, Research, Commercial and Private Patients. The report uses a number of mechanisms to put performance into context, showing achievement against target, in comparison to previous periods and as a trend. The report also identifies additional information and Remedial Action Plans for KPIs falling short of target and requiring improvement.

Executive Summary

The IPR for March 2021 shows that although activity levels have yet to return to the average levels seen during 2019/20, they have significantly recovered from the levels seen in February 2021. Just over 1000 more patients have been seen in A&E in March than February (5,496 vs 4,422) and the total number of elective and non-elective admissions has risen even further (2,633 vs 928). The Trust has seen a good improvement in the number of referrals which have been received (9,537 vs 6,874) and this has resulted in a significant increase in outpatient attendances (45,278 vs 33,855). Although there were two breaches of the 4 hour A&E standard, the Trust was above the national target for this metric.

The Trust again achieved all of the cancer metrics in March, however as expected it did not meet the 18 week RTT incomplete performance target. Patients are predominately being booked in order of referral and this has therefore led to a reduction in the number waiting over 52 weeks however it will be a number of months before the Trust is able to diagnose and treat patients regularly within 18 weeks.

Unfortunately the Trust did not meet the diagnostic waiting time target for the month, however this was due to a small number of patient choosing to delay their non-urgent ultrasound scans to later dates. The worsening of the average call waiting time is symptomatic of the increased volume of calls coming in from patients regarding their care. Although temporary measures are being put in place to address the speed of response, it may be the case that the call volumes do not decrease until patients are being treated within a more acceptable timescale.

As anticipated now that staff have returned to Moorfields from providing support to other organisations they have allowed us to achieve an acceptable ward staffing fill rate. Although we have yet to see an improvement in the percentage of responses to written complaints within 25 days, a significant amount of work is underway to clear the responses which have been delayed the longest due to the pandemic. Although not yet meeting the required standard, appraisal compliance is improving, and the Trust is now achieving compliance with training on information governance.

Action Required/Recommendation

The report is primarily for information purposes but will inform discussion regarding how the Trust is performing against its key organisational measures. This may in turn generate subsequent action.

For Assurance	Х	For decision		For discussion		To Note		
---------------	---	--------------	--	----------------	--	---------	--	--





Context - Overall Activity - March 2021

		March 2021	19/20 Mth 1-11 Average	Year To Date
Accident &	A&E Arrivals (All Type 2)	5,496	8,230	61,173
Emergency	Number of 4 hour breaches	2	124	13
	Number of Referrals Received	9,537	12,051	73,625
Outpatient	Total Attendances	45,278	51,427	340,180
Activity	First Appointment Attendances	8,276	11,392	66,429
	Follow Up (Subsequent) Attendances	37,002	40,035	273,751
	Total Admissions	2,633	3,281	17,947
Admission	Day Case Elective Admissions	2,471	2,944	15,999
Activity	Inpatient Elective Admissions	90	102	704
	Non-Elective (Emergency) Admissions	72	235	1,244

These figures are not subject to any finance or commissioning business logic. They present all activity, whether chargeable or not





March 2021

Operational Metrics

^{**} A&E Performance rounded up, for month performance is at 99.96% and YTD is at 99.98%

Metric Description	Reporting Frequency	Target	Rating	RAP Pg	Previous Period	Current Period	13 Month Series	Year to Date
Cancer 2 week waits - first appointment urgent GP referral	Monthly	≥93%	G		100.0%	100.0%		97.8%
Cancer 14 Day Target - NHS England Referrals (Ocular Oncology)	Monthly	≥93%	G		98.6%	98.8%		94.7%
Cancer 31 day waits - Decision to Treat to First Definitive Treatment	Monthly	≥96%	G		100.0%	100.0%		100.0%
Cancer 31 day waits - Decision to Treat to Subsequent Treatment	Monthly	≥94%	G		100.0%	100.0%		100.0%
Cancer 62 days from Urgent GP Referral to First Definitive Treatment	Monthly	≥85%			100.0%	n/a		100.0%
Cancer 28 Day Faster Diagnosis Standard	Monthly	≥85%	G		100.0%	100.0%		87.2%
18 Week RTT Incomplete Performance *	Monthly	≥92%	R	6	68.0%	69.1%		59.7%
52 Week RTT Incomplete Breaches *	Monthly	Zero Breaches	R	7	555	419		1767
A&E Four Hour Performance **	Monthly	≥95%	G		100.0%	100.0%		100.0%
Percentage of Diagnostic waiting times less than 6 weeks *	Monthly	≥99%	R	8	99.1%	96.9%		64.4%

^{*} Figures for RTT and Diagnostic Waiting Times are provisional





Operational Metrics									
Metric Description	Reporting Frequency	Target	Current	RAP Pg	Previous Period	Current Period	13 Month Series	Year to Date	
Average Call Waiting Time	Monthly	≤ 3 Mins (180 Sec)	R	9	481	618			
Median Clinic Journey Times - New Patient appointments	Monthly	Mth:≤ 95Mins			87	102		n/a	
Median Clinic Journey Times -Follow Up Patient appointments	Monthly	Mth:≤ 85Mins			82	85		n/a	
Theatre Cancellation Rate (Overall)	Monthly	≤7.0%	G		5.3%	4.9%		6.5%	
Theatre Cancellation Rate (Non-Medical Cancellations)	Monthly	≤0.8%	G		0.33%	0.20%		0.49%	
Mixed Sex Accommodation Breaches	Monthly	Zero Breaches	G		0	0		0	
Percentage of Emergency re-admissions within 28 days following an elective or emergency spell at the Provider (excludes Vitreoretinal)	Monthly (Rolling 3 Months)	≤ 2.67%	G		0.00%	0.00%			
VTE Risk Assessment	Monthly	≥95%	G		98.2%	99.4%	V	98.5%	
Posterior Capsular Rupture rates	Monthly	≤1.95%	G		0.00%	0.88%		0.98%	





Quality	and Safety ar	nd Research M	letric	cs				
Metric Description	Reporting Frequency	Target	Rating	RAP Pg	Previous Period	Current Period	13 Month Series	Year to Date
Occurrence of any Never events	Monthly	Zero Events	G		0	0	\triangle	2
Endopthalmitis Rates - Aggregate Score	Quarterly	Zero Non- Compliant	G		1	0	•	
MRSA Bacteraemias Cases	Monthly	Zero Cases	G		0	0	·	0
Clostridium Difficile Cases	Monthly	Zero Cases	G		0	0		0
Escherichia coli (E. coli) bacteraemia bloodstream infection (BSI) - cases	Monthly	Zero Cases	G		0	0		0
MSSA Rate - cases	Monthly	Zero Cases	G		0	0		0
Inpatient (Overnight) Ward Staffing Fill Rate	Monthly	≥90%	G		77.4%	96.4%		98.7%
Inpatient Scores from Friends and Family Test - % positive	Monthly	≥90%	G		94.6%	94.5%		95.2%
A&E Scores from Friends and Family Test - % positive	Monthly	≥90%	G		94.6%	93.5%		94.3%
Outpatient Scores from Friends and Family Test - % positive	Monthly	≥90%	G		92.9%	93.0%	V	93.2%
Paediatric Scores from Friends and Family Test - % positive	Monthly	≥90%	G		96.2%	92.8%	V-V-V	94.7%





Quality	Quality and Safety and Research Metrics								
Metric Description	Reporting Frequency	Target	Current	RAP Pg	Previous Period	Current Period	13 Month Series	Year to Date	
Summary Hospital Mortality Indicator	Monthly	Zero Cases	G		0	0		0	
NHS England/NHS Improvement Patient Safety Alerts breached	Monthly	Zero Alerts	G		0	0			
Percentage of responses to written complaints sent within 25 days	Monthly (Month in Arrears)	≥80%	R	10	76.5%	70.6%		88.1%	
Percentage of responses to written complaints acknowledged within 3 days	Monthly	≥80%	G		94.1%	95.5%		97.0%	
Freedom of Information Requests Responded to Within 20 Days	Monthly (Month in Arrears)	≥90%	G		100.0%	100.0%		95.1%	
Subject Access Requests (SARs) Responded To Within 28 Days	Monthly (Month in Arrears)	≥90%	G		95.1%	98.1%	$\wedge \wedge \vee$	97.9%	
Safer Staffing Checklist - Aggregate Score	Quarterly	Zero Non- Compliant	G		0	0	• • • •		
Number of Serious Incidents remaining open after 60 days	Monthly	Zero Cases	G		0	0		2	
Number of Incidents (excluding Health Records incidents) remaining open after 28 days	Monthly	≤ 20 Open			87	86		n/a	
Total patient recruitment to NIHR portfolio adopted studies (YTD cumulative)	Monthly	≥1800			158	418		1735	
Percentage of Trust Patients Recruited Into Research Projects	Monthly	≥2%	G		5.0%	5.1%		n/a	





F	Remedi	al Acti	on Plar	ո - Mar	ch 202	1	Domain	Service Excellence (Ambitions)	Theme	Patient Ce (Access & C	
	18 We	ek RTT lı	ncomplet	e Perforr	mance		Lead Manager	ead Manager Alex Stamp Responsit			encer
Target	Rating	YTD	Previous	s Period	Current	t Period	100%	* * * * * * * * * * * * * * * * * * *			
≥92%	Red	59.7%	68.	0%	69.	1%	60% - 40% -				
Division	nal Benchi	marking	City Road	North	South	Other	20%				
	(Mar 21)		72.0%	69.5%	63.3%	n/a	461, Wah 1, Inu 1, Ini 1, Was 1, Seb 1, Oct 1, On 1, Oct 1, Jan 5, Epp War 5, Wah 5, Inu 5, Ini 5, Ini 5, Oct 1, On 5, Oct 5, Oc				
	F	Previous	y Identifi	ed Issue:	S		Previous Action Plan(s) to Improve Target Date Stat				
Impact on performance due to Covid-19 deferral of activity and delays caused by second wave.						nd delays	patients and chr plan to 18 week	activity mainly focused on lor onological booking. Pace of re standard dependent on mutua oss London and support for ot ents.	ecovery against al aid	Sep 2021	In Progress (No Update)
	Reaso	ns for Cu	rrent Und	derperfor	mance		Action	Plan(s) to Improve Perfor	rmance	Targe	t Date
No Furthe	No Further Issues and Actions										





F	Remedi	al Acti	on Plar	า - Mar	ch 202	1	Domain	Service Excellence (Ambitions)	Theme	Patient Ce (Access & C	
	52 Week RTT Incomplete Breaches				Lead Manager	Alex Stamp	Responsible Director	Jon Sp	pencer		
Target	Rating	YTD	Previous	s Period	Current	t Period	600				*
Zero Breaches	Red	1767	55	55	4	19	400 300 200		-		
Division	nal Benchi	marking	City Road	North	South	Other	100 0				
	(Mar 21)		79	54	286	n/a	Apr ¹⁹ Mayin ¹⁹ Jul	19 N819 Sep19 Oct19019 Bec19 1902 Fep20 War	biso Waynysolniso Nass	26650 ct500150 Dec50	ustepsy War
	F	Previous	y Identific	ed Issue:	5		Prev	Target Date	Status		
-	n performar y second w		Covid-19	deferral of	activity ar	nd delays	patients and boo	y focused on clearing long-wa king chronologically. Howeve impacted by patient choice.	•	Jul 2021	In Progress (Update)
	Reaso	ns for Cu	rrent Und	derperfor	mance		Action	Plan(s) to Improve Perfor	rmance	Targe	t Date
Impact on performance due to Covid-19 deferral of activity and delays caused by second wave.						nd delays	and this has the over 52 weeks h	dominately being booked in or refore led to a reduction in the lowever it will be a number of to diagnose and treat patients	e number waiting months before	July 2	2021





R	Remedia	al Acti	on Plar	า - Mar	ch 202	1	Domain	Service Excellence (Ambitions)	Theme	Patient Ce (Access & C	
	Å	Average Call Waiting Time					Lead Manager	Alex Stamp	Responsible Director	Jon Sp	encer
Target	Rating	YTD	Previous	Previous Period Current Period			800				
≤ 3 Mins (180 Sec)	Red	n/a	48	31	6	18	600 400 200			/	1
Division	nal Benchm	narking	City Road	North	South	Other	0		10 110 0	•	A A
	(Mar 21)		n/a	n/a	n/a	n/a		119 NB19 Sept Oct 19 01 Dect 1 2020 Feb 20 Mag	•	, ,	usteps, War.
	P	revious	ly Identific	ed Issue:	S		Prev	ious Action Plan(s) to Imp	orove	Target Date	Status
volumes f	Increase in call volumes have resulted in almost double daily call volumes for the team to manage compared to business as usual. This is mainly due to contacting patients				manage arrange Additional Satur review of openir is commencing medium term. 4 with comms tea	s being reviewed as well as someones for staff availability during the sessions being run but loring times is underway. 3) Patiento aim at reducing call volume Process mapped to involve run to send out social message	ring the week. 2) nger-term nt Portal rollout s in short-to- more direct links s if busy.	Jun 2021	In Progress (Update)		
	Reason	s for Cu	rrent Und	derperfor	mance		Action	Plan(s) to Improve Perfor	rmance	Targe	t Date
The worsening of the average call waiting time is symptomatic of the increased volume of calls coming in from patients regarding their care. Although temporary measures are being put in place to address the speed of response, it may be the case that the call volumes do not decrease until patients are being treated within a more acceptable timescale.						heir care. ess the do not	manage arrange Additional Satur review of openir is commencing medium term. 4	s being reviewed as well as someonts for staff availability during the sessions being run but loring times is underway. 3) Patiento aim at reducing call volume) Process mapped to involve run to send out social message	ring the week. 2) nger-term nt Portal rollout s in short-to- more direct links	June	2021





F	Remedi	al Acti	on Plar	า - Mar	ch 202	1	Domain	Service Excellence (Ambitions)	Theme	Patient Ce (Access & C		
Percen	Percentage of Diagnostic waiting times less than 6 weeks			Lead Manager	Jessica Neece	Responsible Director	Jon Sp	oencer				
Target	Rating	YTD	Previous	s Period	Current	Period	100%	*************************************			\	
≥99%	Red	64.4%	99.	1%	96.	9%	60% 40% 20%					
Division	nal Benchi	marking	City Road	North	South	Other	0%					
	(Mar 21)		96.7%	n/a	100.0%	n/a	Apr May 1 Jun 19 Ju	7179 NB 73 EB 70 CF MON DECT 3 245 EB 50 W 34.5	Wans Inuso Inisone	2eb50ct50050bec50	an2tep51 yar21	
	F	Previous	ly Identific	ed Issue	S		Prev	ious Action Plan(s) to Imp	orove	Target Date	Status	
continuin	Position improved from January in line with recovery. Services are continuing to work through the backlog following suspension of medium and low risk activity. Patient choice is still having an impact.					of		rking with the relevant patient y an appointment date.	s to reassure	Apr 2021	In Progress (Update)	
	Reaso	ns for Cเ	ırrent Unc	derperfo	rmance		Action	Plan(s) to Improve Perfor	rmance	Targe	t Date	
Position improved slightly from February (96.1% to 96.9%) in line with recovery. Services are continuing to schedule medium and low risk patients whose original appointments were postponed, this is helping to reduce the backlog. Fewer patients are refusing appointments due to Covid safety concerns, this is enabling the backlog to be cleared at a slightly quicker rate.						w risk helping ents due		ntiunuing to schedule appointr rrisk patients with the aim to deter two.		June	2021	





F	Remedi	al Acti	on Plar	n - Mar	ch 202	1	Domain	Service Excellence (Ambitions)	Theme	Patient Ce (Quality	ntred Care & Safety)
Percen	ercentage of responses to written complaints sent within 25 days (Month in Arrears)			Lead Manager	Tim Withers	lan Tom	nbleson				
Target	Rating	YTD	Previous	s Period	Current	Period	100%				
≥80%	Red	88.1%	76.	5%	70.	6%	60% 40% 20%			V	
Divisio	nal Bench	marking	City Road	North	South	Other	0%				
	(Feb 21)		70.0% 100.0% 100.0% 33.3%				Apr May 1 Jun 19 Ju	717 MR 13 Eb 70 Ct 70 N Dec 1 3 W 5 Eb 50 W 3 L	Abr Mans Inuso Iniso	50 b50 c550 NON Dec50	austepsyausz
Previously Identified Issues							Prev	ious Action Plan(s) to Imp	prove	Target Date	Status
Four of 17 complaints breached during January. These were for City Road and were due to Covid related staff issues particularly sickness and leave creating planning issues. One more complaint meeting the deadline would have generated a 'met' target					sickness	_	ues have now been resolved s met in April and stability to the	-	Apr 2021	In Progress (Update)	
	Reasons for Current Underperformance						Action	Plan(s) to Improve Perform	rmance	Targe	t Date
Of the 17 complaints received, five breached the KPI for response time. One was for Transport managed by DHL/ Royal Free and four were for City Road who are currently reorganising the way complaints are managed which had yet to settle in in February.						nd four	Managers. Proc	ng being delivered to City Roa ess established to ensure clin are turned around faster.		April	2021





Enablers (People, Infrastructure & Culture and Financial Health & Enterprise)

"Enabler" Metrics								
* Figures unavailable at time of report production due to year end report Metric Description	Reporting Frequency	further comment	Rating Rating	RAP Pg 993	Finance Re Previous Period	Current Period	13 Month Series	Year to Date
Appraisal Compliance	Monthly	≥80%	R		76.4%	78.2%	None and the same of the same	
Information Governance Training Compliance	Monthly	≥95%	G		94.3%	95.1%	~~~	
Staff Turnover (Rolling Annual Figure)	Monthly	≤15%	G		9.7%	9.4%		
Proportion of Temporary Staff	Monthly	RAG as per Spend		*	7.8%	Due May		6.7%
Data Quality - Ethnicity recording (Outpatient and Inpatient)	Monthly	≥94%	G		96.9%	96.9%		94.6%
Data Quality - Ethnicity recording (A&E)	Monthly	≥94%	G		100.0%	100.0%		100.0%
70 Day To Recruit First Research Patient	Monthly	≥80%	G		100.0%	100.0%		97.7%
Percentage of Research Projects Achieving Time and Target	Monthly	≥65%	G		77.8%	75.0%		71.9%
Percentage of Patients Recruited Against Target (Studies Closed In Month)	Monthly	100%	G		109.7%	103.1%		105.3%
Overall financial performance (In Month Var. £m)	Monthly	≥0		*	1.95	Due May	~~~	Due May
Commercial Trading Unit Position (In Month Var. £m)	Monthly	≥0		*	-0.77	Due May		Due May





F	Remedi	al Acti	on Plar	ո - Mar	ch 202	 1	Domain	People (Enablers)	Theme	Workforc	e Metrics
-		Appraisal Compliance			Lead Manager	Bola Ogundeji	Responsible Director	Sandi [
Target	Rating	YTD	Previous	s Period	Current	Period	90%				
≥80%	Red	n/a	76.4	4%	78.2%						***
Division	nal Benchr	marking	City Road	North	South	Other	60%		r.0 11 r.0 10 10		
	(Mar 21)		n/a	n/a	n/a	n/a	,	79 Mar 2667 Oct 100 10 Oct 13 W 20 10 Mar	biso Walnusolnisonas		
	Previousl	y Identifi	ed Issues	S			Previous Acti	on Plan(s) to Improve		Target Date	Status
of reminder emails to communicating appr. The learning and devented undertake appraisals on Monitoring expiration by the planning should be seen to be seen the seen to be seen						r emails to ating appragand deviappraisals oring expirit where theretaking and reporting training regroup coac	managers is now in its in the initial rates with Divisuelopment team are remotely and have its and sending rere is no response. It is to understanding this back to the frequirement linked thing.	o the e-appraisal tool is identified	rs are monthly basis. to managers to uding: th weekly	Mar 2021	In Progress (Update)
Reaso	ns for Cu	rrent Un	derperfor	mance		, ,	Action Plan(s) t	o Improve Performance		Targe	t Date
Remote v	vorking and	I Covid pr planning	essure and	l recovery	of reminde communica The learnir undertake Monitiescalation the remind Underworkload at When 121/small general appraisal aface to face monitored We all	r emails to ating appraisals oring expiri where there er email to taking and reporting regroup coaceam are tance by sendad a deadle appraisal by L&D. The also projetion team i	managers is now in itsal rates with Diviselopment team are remotely and have its and sending rerie is no response. A support managers allysis to understand go this back to the Hequirement linked thing. It is a targeted application of the for completion is as corporate staff posing to launch are	the for virtual appraisal is on-going a operation. HR Business Partnetional Management Teams on a salso providing additional support implemented an action plan inclininders to staff and managers with we will be attaching objective set reasons for non-compliance egangements. The e-appraisal tool is identified to the e-appraisal tool is identified roach within corporate services to the e-appraisal tool is reflects of increasingly return to the office. Appraisals awareness week suppose. This would focus on post-CC in the control of the contro	rs are monthly basis. It to managers to uding: Ith weekly Itting guidelines to absence, If, the team offer Ito drive up lower requiring opportunities for This will be	May :	2021





Report title	Monthly Finance Performance Report Month 12 – March 2021
Report from	Jonathon Wilson, Chief Financial Officer
Prepared by	Justin Betts, Deputy Chief Financial Officer
Link to strategic objectives	Deliver financial sustainability as a Trust

Executive summary

All NHS organisation were issued with revised control totals for the final six months of the year following mandated reported positions of breakeven for Months 1-6.

This report represents the Trusts re-revised 2020/21 financial plan submitted to NHSI in November 2020 in which the Trust has planned a break-even positon (nil control total).

For March the Trust is reporting :-

- a £0.44m deficit adjusting for block payment and STP income support (£6.16m YTD);
- a deficit of £3.62m prior to block payment support (£75.50m YTD);

Compared to plan, the Trust is reporting:-

- £3.28m less income from directly commissioned clinical activity than would be expected, (£83.13m YTD) offset by £3.18m block payment and STP income support;
- **£1.21m more income** driven by improved commercial income and central funding for increased annual leave;
- £0.29m less pay, and
- £1.27m more non-pay operating expenditure.

Financial Performance		1	In Month		1			
£m	Annual Plan	Plan	Actual	Variance	Budget	Actual	Variance	%
Income	£251.3m	£23.2m	£24.2m	£1.0m	£251.3m	£237.3m	(£14.0m)	(6)%
Pay	(£133.7m)	(£11.5m)	(£11.2m)	£0.3m	(£133.7m)	(£128.5m)	£5.2m	4%
Non Pay	(£108.6m)	(£11.2m)	(£12.4m)	(£1.3m)	(£108.6m)	(£93.7m)	£14.9m	14%
Financing & Adjustments	(£9.1m)	(£0.8m)	(£1.0m)	(£0.2m)	(£9.1m)	(£9.0m)	£0.0m	0%
CONTROL TOTAL	£0.0m	(£0.3m)	(£0.4m)	(£0.1m)	£0.0m	£6.2m	£6.2m	

Quality implications

Patient safety has been considered in the allocation of budgets.

Financial implications

Delivery of the financial control total will result in the Trust being eligible for additional benefits that will support its future development.

Risk implications


Potential risks have been considered within the reported financial position and the financial risk register is discussed at the Audit Committee.

Action Required/Recomm The board is asked to cons		rep	ort.			
For Assurance	For decision		For discussion	✓	To note	✓





Presented by	Jonathan Wilson; Chief Financial Officer
Prepared by	Justin Betts; Deputy Chief Finance Officer Amit Patel; Head of Financial Management Lubna Dharssi, Head of Financial Control Richard Allen; Head of Income and Contracts



Monthly Finance Performance Report

For the period ended 31st March 2021 (Month 12)

Key Messages

Statement of Comprehensive Income

Full year	reported
financial	position

For the financial year ended 31st March 2021, the Trust is reporting an internal NHSI regulatory performance surplus of £6.163m;

Financial Position For March the Trust is reporting:-

£0.435m deficit Including support

- a £0.44m deficit adjusting for block payment income support;
- a deficit of £3.62m prior to block payment support (£75.50m YTD);

Compared to the revised plans, the Trust is reporting:-

- £2.07m less income than would be expected pre-support; offset by
- £0.29m less pay; and
- £1.27m more non-pay operating expenditure

Income

Total trust income is £2.07m less than would be expected, consisting of:-

£2.07m less than plan pre support

- Commissioned Clinical activity income losses £3.28m; (£83.13m YTD)
- Other Clinical activity income losses £0.37m; (£3.38m YTD)
- Commercial income gains £0.31m; (£5.01m YTD)
- Research income gains £0.24m; (£1.94m losses YTD) and
- Other income gains of £1.04m; (£0.93m YTD losses).

Directly commissioned activity income, if reimbursed by normal contracting arrangements would total £12.72m compared to a plan of £16.00m - £3.28m adverse to plan.

Expenditure

£0.99m adverse to

(pay, non pay, excl financing)

Pay costs are £0.29m favourable to plan. Temporary staffing has seen a significant increase on prior months in March linked to the activity increase. In addition there have been pressures on temporary staffing due to staff shielding, social distancing and reduced lists.

Non-pay costs are £1.27m adverse to plan mainly due to higher than expected activity contributing to increased drug and clinical consumable costs.



Cash and Working Capital Position	The cash balance at the 31 st March is £68.4m significantly higher than plan, primarily due to block income payments in advance, and top-up payments received by the Trust to ensure NHS organisations have sufficient cash to deal with the initial emergency COVID response.
Capital (both gross capital	Capital spend to 31st March 2021 totalled £17.5m, inclusive of external and COVID funded elements.
expenditure and CDEL)	Trust funded schemes totalled £16.3m, against the revised £13.7m plan, an approved £2.6m over commitment largely linked to additional investment in Community diagnostic hubs, investment in medical equipment replacement programmes, and in commercial areas.
Use of Resources	Current use of resources monitoring has been suspended.

Trust Financial Performance - Financial Dashboard Summary

FINANCIAL PERFORMANCE

Financial Performance		1	In Month		i	Year to Date			
£m	Annual Plan	Plan	Actual	Variance	Budget	Actual	Variance	%	RAG
Income	£251.3m	£23.2m	£24.2m	£1.0m	£251.3m	£237.3m	(£14.0m)	(6)%	
Pay	(£133.7m)	(£11.5m)	(£11.2m)	£0.3m	(£133.7m)	(£128.5m)	£5.2m	4%	
Non Pay	(£108.6m)	(£11.2m)	(£12.4m)	(£1.3m)	(£108.6m)	(£93.7m)	£14.9m	14%	
Financing & Adjustments	(£9.1m)	(£0.8m)	(£1.0m)	(£0.2m)	(£9.1m)	(£9.0m)	£0.0m	0%	
CONTROL TOTAL	£0.0m	(£0.3m)	(£0.4m)	(£0.1m)	£0.0m	£6.2m	£6.2m		
CONTROL TOTAL	20.0111	(20.311)	(20.411)	(20.1111)	20.0111	20.2111	20.2111		
Memorandum Items									
Research & Development	(£2.19m)	(£0.17m)	(£0.70m)	(£0.52m)	(£2.19m)	(£6.69m)	(£4.50m)	(205)%	

(£0.08m)

£0.08m

£4.14m

(£2.45m)

(£0.45m)

(£1.05m)

(£4.59m)

£1.40m

(111)%

57%

PAY AND WORKFORCE


Commercial Trading Units

ORIEL Revenue

TOTAL PAY	(£133.7m)	(£11.5m)	(£11.2m)	£0.29m	(£133.7m)	(£128.5m)	£5.21m	
Other	(£0.5m)	(£0.0m)	(£0.0m)	£0.00m	(£0.5m)	(£0.4m)	£0.01m	0%
Agency	(£2.5m)	(£0.2m)	(£0.2m)	(£0.06m)	(£2.5m)	(£1.7m)	£0.76m	1%
Bank	(£11.1m)	(£0.9m)	(£1.1m)	(£0.11m)	(£11.1m)	(£7.3m)	£3.79m	6%
Employed	(£119.7m)	(£10.4m)	(£9.9m)	£0.46m	(£119.7m)	(£119.0m)	£0.66m	93%
£m	Annual Plan	Plan	Actual	Variance	Budget	Actual	Variance	Total
Pay & Workforce	Annual Dlan	In Month					%	

£0.25m

(£0.14m)




£4.14m

(£2.45m)

£0.33m

(£0.21m)



INCOME BREAKDOWN RELATED TO ACTIVITY

Income Breakdown	Annual	1	Year to Date	Forecast				
£m	Plan	Budget	Actual	Variance	RAG	Plan	Actual	Variance
NHS Clinical Income	£145.1m	£145.1m	£70.7m	(£74.4m)			-	-
Pass Through	£39.8m	£39.8m	£31.1m	(£8.7m)		-	-	-
Other NHS Clinical Income	£9.3m	£9.3m	£6.0m	(£3.4m)		-	-	-
Commercial Trading Units	£29.3m	£29.3m	£24.3m	(£5.0m)		-	-	-
Research & Development	£14.7m	£14.7m	£12.7m	(£1.9m)		-	-	-
Other	£11.8m	£11.8m	£10.9m	(£0.9m)		-	-	-
INCOME PRE TOP-UP	£250.1m	£250.1m	£155.7m	(£94.4m)		-	-	-
FRF/Block Payment Top Up	£1.3m	£1.3m	£81.7m	£80.4m		-	-	-
TOTAL OPERATING REVENUE	£251.3m	£251.3m	£237.3m	(£14.0m)		-	-	-


RAG Ratings Red > 3% Adverse Variance, Amber < 3% Adverse Variance, Green Favourable Variance, Grey Not applicable

CASH, CAPITAL AND OTHER KPI'S

Capital Programme	Annual		Year to Date				Forecast			
£m	Plan	Budget	Actual	Variance	RAG	Budget	Actual	Variance		
Trust Funded	(£13.7m)	(£13.7m)	(£16.3m)	£2.6m						
Donated/Externally funded	(£1.8m)	(£1.8m)	(£1.3m)	(£0.6m)						
TOTAL	£15.5m	£15.5m	£17.5m	£2.0m		-	-	-		

Key Metrics	Plan	Actual	RAG
Cash	46.7	68.4	
Debtor Days	45	30	
Creditor Days	45	43	
PP Debtor Days	65	62	
Use of Resources	Plan	Actual	
			ı
Capital service cover rating	-	-	
Liquidity rating	-	-	
I&E margin rating	-	-	
I&E margin: distance from fin. plan	-	-	
Agency rating	-	-	
OVERALL RATING	-	-	

Net Receivables/Ageing £m



Trust Income & Expenditure Performance

Statement of Comprehensive	امديما		In Month				Year to Date				
Statement of Comprehensive Income £m	Annual Plan	Plan	Actual	Variance	%	RAG	Plan	Actual	Variance	%	F
Income											
NHS Commissioned Clinical Income	184.90	16.00	12.72	(3.28)	(21)%		184.90	101.77	(83.13)	(45)%	
Other NHS Clinical Income	9.35	0.82	0.45	(0.37)	(45)%		9.35	5.97	(3.38)	(36)%	
Commercial Trading Units	29.35	2.69	3.00	0.31	11%		29.35	24.34	(5.01)	(17)%	
Research & Development	14.67	2.09	2.32	0.24	11%		14.67	12.72	(1.94)	(13)%	
Other Income	11.79	1.49	2.53	1.04	69%		11.79	10.86	(0.93)	(8)%	
Total Income	250.06	23.10	21.03	(2.07)	(9)%		250.06	155.67	(94.38)	(38)%	-
Operating Expenses											
Pay	(133.68)	(11.53)	(11.24)	0.29	2%		(133.68)	(128.46)	5.21	4%	
Drugs	(39.74)	(3.86)	(3.84)	0.01	0%		(39.74)	(30.32)	9.42	24%	
Clinical Supplies	(21.47)	(2.05)	(1.73)	0.32	15%		(21.47)	(14.44)	7.03	33%	
Other Non Pay	(47.39)	(5.26)	(6.86)	(1.60)	(30)%		(47.39)	(48.92)	(1.53)	(3)%	
Total Operating Expenditure	(242.28)	(22.69)	(23.68)	(0.99)	(4)%		(242.28)	(222.15)	20.13	8%	-
EBITDA	7.77	0.41	(2.65)	(3.06)	(750)%		7.77	(66.48)	(74.25)	(955)%	
Financing & Depreciation	(9.35)	(0.86)	(1.36)	(0.50)	(57)%		(9.35)	(9.93)	(0.58)	(6)%	
Donated assets/impairment adjustments	0.29	0.05	0.39	0.34	686%		0.29	0.91	0.61	209%	
Control Total Surplus/(Deficit) Pre FRF/Top Up Payments	(1.28)	(0.41)	(3.62)	(3.21)	(790)%		(1.28)	(75.50)	(74.22)	(5,787)%	-
Provider PSF/FRF	0.84	0.21	-	(0.21)			0.84	-	(0.84)		
Covid Block Payments Received	-	-	1.99	1.99			-	77.27	77.27		
Covid Top Up Payments	0.45	(0.11)	1.19	1.30			0.45	4.40	3.95		
Post PSF/FRF Control Total Surplus/(Deficit)	0.00	(0.31)	(0.44)	(0.13)	(42)%		0.00	6.16	6.16		-

Commentary

Operating Clinical activity levels recorded were 74% during March (February Income 64%) of 2019/20 levels. If the Trust was reimbursed under activitybased contracting arrangements, income would have totalled £12.72m

plan pre support

£2.07m below - £3.28m lower than the block income payment received by the Trust.

Other income variances include:-

- · Commercial Trading income was £0.31m favourable linked to increased demand;
- Research £0.24m favourable further to full year income receipts;
- Other NHS Clinical Income £0.37m adverse, due to reduced activity at sub-commissioned sites;
- Other income was £1.04m favourable due to central annual leave funding (£0.68m), additional Q5 HEE funding (£0.23m) and Covid-19 cost funding (£0.17m)

Employee Total pay costs were £0.29m favourable to plan, with bank and agency Expenses costs £1.29m, similar to March 2020 levels and £0.42m higher than the rolling 3 month average.

£0.29m below

There were material increases in temporary staffing costs in month across all clinical staff groups primarily due to increased activity, but compounded by staff shielding, annual leave, social distancing and reduced lists.

Non Pay Non pay costs were £1.27m adverse to plan due to a combination of Expenses increased drug and clinical consumable costs linked to activity increases.

£1.27m above

Drug expenditure and clinical consumables were £1.11m and £0.56m (non pay and higher than the previous rolling 3 months respectively.

financing)

Trust Patient Clinical Income Performance


PATIENT ACTIVITY AND CLINICAL INCOME

Point of Delivery	Act	ivity In Mor	nth			Activity YTD			YTE	Income £'000	•
	Plan	Actual	Variance	%	Plan	Actual	Variance	%	Plan	Actual Variand	е %
AandE	9,489	5,498	(3,991)	58%	105,701	61,181	(44,520)	58%	£16,484	£9,000 (£7,48	4) 55%
Daycase / Inpatients	3,525	2,547	(978)	72%	38,007	16,716	(21,291)	44%	£42,440	£20,192 (£22,24	7) 48%
High Cost Drugs	5,172	5,035	(138)	97%	55,772	47,396	(8,377)	85%	£36,414	£31,110 (£5,30	4) 85%
Non Elective	255	73	(182)	29%	3,006	1,261	(1,745)	42%	£5,874	£2,531 (£3,34	3) 43%
OP Firsts	12,456	7,449	(5,007)	60%	134,312	58,791	(75,521)	44%	£23,086	£10,067 (£13,0	9) 44%
OP Follow Ups	45,295	36,089	(9,206)	80%	488,399	276,031	(212,368)	57%	£50,309	£25,510 (£24,80	0) 51%
Other NHS clinical income									£4,292	£1,099 (£3,19	3) 26%
Total	76,192	56,691	(19,502)	74%	825,197	461,376	(363,822)	56%	£178,900	£99,509 (£79,39	1) 56%

Income Figures Excludes CQUIN, Bedford, and Trust to Trust test income

RAG Ratings Red to Green colour gradient determined by where each percentage falls within the range

ACTIVITY TREND



Commentary

NHS Income Activity levels recorded during March were 74% of the 2020/21 activity plan levels (prior month: 64%).

> Please note this is a different metric to NHSI's assessment of performance for Pre-COVID activity levels based on prior year activity levels.

> The charts to the left demonstrate the in year activity levels compared to previous years highlighting the material shift in activity as a result of COVID, and the pace of recovery towards pre-COVID activity levels.

> NHS Patient Clinical activity income in March was £12.3m if reimbursed via activity based contracting arrangements £4.2m less than planned prior to top-up income shown on slide four.

Trust Statement of Financial Position – Cash, Capital, Receivables and Other Metrics


CAPITAL EXPENDITURE

Capital Expenditure	Annual	,	Year to Da	te
£m	Plan	Plan	Actual	Variance
Estates - Trust Funded	1.6	1.6	1.6	0.0
Medical Equipment - Trust Funded	3.4	3.4	7.8	4.4
IT - Trust Funded	1.3	1.3	1.5	0.2
ORIEL - Trust Funded	5.8	5.8	3.6	(2.2)
Dubai - Trust funded	0.5	0.5	0.7	0.2
Other - Trust funded	1.2	1.2	1.2	(0.0)
TOTAL - TRUST FUNDED	13.7	13.7	16.3	2.6
Covid/Donated/Externally funded	1.8	1.8	1.3	(0.6)
TOTAL INCLUDING DONATED	15.5	15.5	17.5	2.0

Capital Funding £m	Annual Plan	Secured	Not Yet Secured	% Secured
Planned Total Depreciation	8.0	8.0		100%
Cash Reserves - B/Fwd cash	7.6	7.6		100%
Cash Reserves - Other (PSF)	-	-		0%
Capital Loan Repayments	(1.8)	(1.8)		100%
TOTAL - TRUST FUNDED	13.7	13.7	-	100%
Donated/Externally funded	0.4	0.4		100%
COVID Funding	1.4	1.4		100%
TOTAL INCLUDING DONATED	15.5	15.5	-	100%

RECEIVABLES

Net Receivables £m	0-60 Days	60-180 Days	180+ Days	2018/19 +	Total
CCG Debt	(2.3)	-		-	(2.3)
Other NHS Debt	3.6	4.6	0.4	0.3	8.8
Non NHS Debt	0.8	1.1	1.9	0.3	4.0
Commercial Unit Debt	1.3	0.7	0.4	0.1	2.4
TOTAL RECEIVABLES	3.4	6.3	2.7	0.6	13.0



STATEMENT OF FINANCIAL POSITION

Statement of Financial	Annual	Year to Date				
Position £m	Plan	Plan	Actual	Variance		
Non-current assets	103.0	103.0	103.7	0.7		
Current assets (excl Cash)	12.0	12.0	22.0	10.0		
Cash and cash equivalents	46.7	46.7	68.4	21.7		
Current liabilities	(35.4)	(35.4)	(60.5)	(25.1)		
Non-current liabilities	(35.4)	(35.4)	(36.0)	(0.6)		
TOTAL ASSETS EMPLOYED	91.0	91.0	97.7	6.7		

OTHER METRICS

Use of Resources	Weighting	Plan YTD	Score
Capital service cover rating	20%	-	-
Liquidity rating	20%	-	-
I&E margin rating	20%	-	-
I&E margin: distance from financial pl	20%	-	-
Agency rating	20%	-	-
OVERALL RATING		-	-

Commentary

Cash and The cash balance as at the 31st March 2021 was £68.5m Working significantly higher than initially planned, due to block Capital income. Cash receipts in advance from commissioners were recovered as expected in March.

Expenditure

Capital Revised capital allocations for Trusts, and STP's were notified in May with a limit of £13.7m for the Trust. This was subsequently increased to cover increased capital expenditure in agreement with the ICS.

> Capital spend to March totalled £17.5m largely linked to Oriel, ophthalmology community diagnostic hub and purchases of new medical equipment.


Use of Use of resources monitoring and reporting has been Resources suspended.

Receivables Receivables have reduced by £7.2m since the end of the 2019/20 financial year to £13m. An reduction of £4.6m was recorded in March from the February position.

Payables Payables totalled £27.3m at the end of March, a increase of £11.5m since March 2020. The increase is due to invoices for significant capital spend in March this year, other NHS bodies catching up with provider to provider billing and UCL Hercules project.

Trust Statement of Financial Position – Cashflow

Cash Flow £m	Apr Actuals	May Actuals	Jun Actuals	Jul Actuals	Aug Actuals	Sep Actuals	Oct Actuals	Nov Actuals	Dec Actuals	Jan Actuals	Feb Actuals	Mar Actuals	Outturn Total	Mar Plan	Mar Var
Opening Cash at Bank	52.4	68.4	72.7	76.7	80.8	82.0	83.6	83.3	84.3	82.6	81.6	81.1	52.4		
Cash Inflows															
Healthcare Contracts	33.3	15.2	15.2	15.2	15.2	15.1	16.4	15.8	13.9	13.9	14.8	2.6	186.4	-	2.6
Other NHS	3.9	2.6	1.6	1.9	0.5	1.2	0.5	1.9	0.9	0.9	2.3	1.0	19.2	1.5	(0.5
Moorfields Private/Dubai	1.4	0.9	1.6	2.6	2.8	3.3	3.9	4.0	3.3	2.3	1.9	3.8	31.8	1.9	1.9
Research	1.1	0.6	1.0	2.7	0.8	1.1	1.0	1.1	0.7	0.0	1.6	2.5	14.2	1.0	1.5
VAT	0.4	0.5	0.2	-	0.5	-	0.2	0.2	0.2	0.5	0.6	0.3	3.7	0.4	(0.1
PDC	-	-	-	0.3	-	-	-	-	-	-	-	1.6	2.0	1.6	-
PSF	-	0.2	-	-	-	-	-	-	-	-	-	-	0.2	-	-
Other Inflows	0.2	1.8	0.4	0.4	0.3	0.4	0.5	0.4	2.0	0.1	0.4	0.7	7.6	0.4	0.3
Total Cash Inflows	40.3	21.8	19.9	23.1	20.1	21.1	22.5	23.4	21.1	17.7	21.6	12.6	265.1	6.8	5.
Cash Outflows															
Salaries, Wages, Tax & NI	(9.6)	(9.6)	(9.4)	(9.4)	(9.4)	(9.6)	(9.7)	(9.6)	(9.7)	(9.7)	(9.7)	(9.7)	(115.1)	(9.7)	(0.
Non Pay Expenditure	(10.6)	(6.7)	(5.4)	(8.1)	(7.3)	(7.8)	(11.4)	(9.0)	(11.4)	(7.0)	(10.1)	(8.8)	(103.5)	(10.2)	1.4
Capital Expenditure	(1.0)	(0.4)	(0.4)	(0.6)	(0.5)	(0.2)	(0.3)	(0.4)	(0.6)	(8.0)	(0.4)	(4.8)	(10.5)	(1.9)	(2.
Oriel	(2.3)	(0.1)	(0.1)	(0.2)	(0.2)	(0.3)	(0.3)	(2.2)	(0.2)	(0.3)	(0.2)	(0.2)	(6.7)	(1.3)	1.0
Moorfields Private/Dubai	(0.9)	(0.7)	(0.8)	(0.6)	(0.7)	(0.8)	(1.1)	(0.7)	(8.0)	(0.9)	(1.1)	(0.9)	(10.0)	(1.1)	0.3
Financing - Loan repayments	-	-	-	-	(0.7)	(0.8)	-	-	-	-	(0.7)	(8.0)	(2.9)	(8.0)	-
Dividend and Interest Payable	-	-	-	-	-	-	-	(0.6)	-	-	-	-	(0.6)	-	-
Total Cash Outflows	(24.4)	(17.5)	(16.0)	(19.0)	(18.8)	(19.5)	(22.8)	(22.4)	(22.7)	(18.7)	(22.1)	(25.2)	(249.2)	(24.9)	(0.
Net Cash inflows /(Outflows)	15.9	4.3	4.0	4.1	1.3	1.6	(0.3)	0.9	(1.7)	(1.0)	(0.5)	(12.7)	-	(18.1)	5.4
Closing Cash at Bank 2020/21	68.4	72.7	76.7	80.8	82.0	83.6	83.3	84.3	82.6	81.6	81.1	68.4	68.4		
Closing Cash at Bank 2020/21 Plan	39.5	39.1	38.6	40.4	37.7	35.5	36.8	36.2	34.4	34.8	32.8	29.3	29.3		
Closing Cash at Bank 2019/20	45.1	42.6	41.0	48.9	47.8	49.6	49.6	49.5	50.3	52.6	53.8	52.4	52.4		



Commentary

Cash flow The cash balance at the 31st March is £68.4m, significantly higher than initially planned.

> The interim financial regime introduced to support NHS organisations during the CVOID response has contributed to significantly higher cash balances than previously planned, designed to ensure sufficient cash is available to the NHS to implement any required changes. The Trust currently has 103 days (prior month: 122 days) of operating cash.

> As a result the Trust has an additional focus towards liquidity and working capital management to ensure sufficient cash is available to respond to emergency demand for supplies, staff, and suppliers payments.

> In addition all NHS organisation received additional guidance on Prompt Payment to suppliers of the NHS, to ensure their cash flows are supported wherever possible.

> March saw a cash outflow of £12.7m against a plan of £18.1m outflow as receipts were higher than forecast.





Agenda item 11
Report of the audit and risk committee
Board of directors 22 April 2021

Report title	Report of the audit and risk committee	
Report from	Nick Hardie, chairman, audit and risk committee	
Prepared by	Helen Essex, company secretary	
Link to strategic objectives	We will have an infrastructure and culture that supports innovation	
	We are able to deliver a sustainable financial model	

Brief summary of report

Attached is a brief summary of the audit and risk committee meeting that took place on 13 April 2021.

Action Required/Recommendation.

- The Board is asked to NOTE the report of the audit and risk committee and gain assurance from it.
- The Board is asked to CONSIDER and APPROVE the following statement:

'The going concern basis is appropriate for the trust's accounts and this assessment is based on the services it provides continuing to be provided with the same assets in the public sector.'

If the board is satisfied that the statement applies then the below will be included in the Annual Report and Accounts:

"After making enquiries, the directors have a reasonable expectation that the services provided by the NHS foundation trust will continue to be provided by the public sector for the foreseeable future. For this reason, the directors have adopted the going concern basis in preparing the accounts, following the definition of going concern in the public sector adopted by HM Treasury's Financial Reporting Manual."

For Assurance 🗸	For decision 🗸	For discussion	To note	
-----------------	----------------	----------------	---------	--

AUDIT AND RISK COMMITTEE SUMMARY REPORT – 13 APRIL 2021 Governance Quorate - Yes Attendance (membership) - 100% Internal audit Quality governance – amber/green There were mature, well-embedded arrangements in place going in to the pandemic and there has been no need to significantly amend those arrangements. The low level recommendations focus on working on consistency across divisions and how they embed learning and discuss within divisional meetings. Internal audit recommendation tracker There were no outstanding items on the tracker. IT resilience will come to the next audit committee. External audit There are likely to be significant risks for the financial statements audit but this will be common due to revenue recognition and changes in the way the NHS has been funded via the block contract. Risks of significant weakness relate to the ability to audit Oriel, longer term strategic direction, post-Covid environment and cost savings. This is due to similar problems to the previous year in being able to complete tasks and get access to documents. An annual auditor's report will be provided on the vfm conclusion that includes a written narrative about trust arrangements.

Current activity (as at date of meeting)

Salary overpayments

• Process issues have been identified and rectified and these relate to the leaver process and fixed term contract position.

about particular estimates in the accounts, the going concern review, etc. The committee will discuss this further at the extraordinary meeting in June.

Discussion took place about the accounting issues at University Hospitals Leicester and what migitations are in place at MEH to prevent something similar happening.

The committee was advised that there are a number of tangible assurances that can

be given to the board such as clear demonstration of challenge to management

- It was acknowledged that there will always be an element of salary overpayments but that the aim is get to an appropriate tolerance level where they are minimised as far as possible.
- A helpdesk has been established to manage ESR queries so that there is a clear process of monitoring.
- Refresher training has been implemented for the HR team and managers with responsibilities identified to attend training.
- Recruitment will take place for a payroll specialist and head of HR operations to work on clearing the backlog and managing the process.
- The next steps are to continue with the implementation plan and escalations, evaluation of the dispute procedure and month end deadline processes, and to build a benefits realisation plan for workforce system integration and contract performance management with SBS.

Board assurance framework

 Covid risk has reduced due to the continuing mitigations, although will be kept under close review.

- Risk relating to recovery of clinical services needs close scrutiny due to the concerns raised over managing the backlog and risk stratification of patients.
- Assurance on this issue is being sought by the recovery oversight committee via the service directors.
- The workforce planning risk score has been increased due to the need to expedite and align with new models of care.
- The risk on staff health and wellbeing is being well mitigated through a number of iniatives being put in place and is being monitored through the people committee.
- A new risk has been added on digital resilience and consideration is being given as
 to whether the specific risk relating to cyber can be managed through the corporate
 risk register process.
- The Brexit risk is to be de-escalated and managed through the corporate risk register
 process although the issue of overseas visitors has been raised and will be factored
 in to any mitigating actions.
- Emerging themes from the corporate risk register relate to HR systems interoperability, capacity and resource in place for EDI and digital save systems.

Counter fraud report

- The committee received a progress report setting out activity since the last meeting.
- The primary focus has been finalising reviews in the 'prevent and deter' sphere.
- One ongoing case relates to claims for maternity leave and attempts are being made to verify the veracity of the claims.
- The annual report and return need to be drafted for the end of May and the trust will be required to self-assess under the new government counter fraud functional standards.
- Procurement (pre-contract) and invoice reviews contain low priority recommendations and requirements.
- Cyber is not a mandated area but has been identified as a key area of focus.
- Cyber fraud risks are broader than technical protection and the team is agreeing a quarterly programme of tailored awareness sessions for individuals across the trust.

<u>Annual review of going concern (please see commentary under 'action required/recommendation'</u>

London Claremont accounting

- The trust acquired the business in December and received external advice, following IFRS 3 (business combinations).
- This relates to key areas on the balance sheet, assets and liabilities and intangible assets which are being held at cost although a test for impairment will be done at the end of the year.

Amendments to SFIs

• The following amendments to SFIs were approved:

Losses and special payments — all exit packages must be authorised by the HR director and all reported to finance. External consent is required for payments over a certain limit and particularly if there is a PILON cost of more than £50k.

London Claremont limits – scheme of delegation is now included and to be reviewed in relation to limits and their appropriateness.

ESCROW account – this relates to holding monies in partnership and any such account is to be authorised by the CFO.

	Losses and special payments • Since the last meeting the trust recorded losses of £80k on 101 cases (private), £1500 on 12 cases (NHS) and nothing on UAE as debt is written off at the end of the financial year. In total private losses amount to £210k and NHS losses amount to £166k.
Key concerns	 ICS arrangements are not formalised and there are new arrangements coming in at a time of great change so likely to be a number of gaps that emerge. Potential sector-wide changes that might hinder progress in corporate services from being embedded. Vaccination of frontline staff and how the risk is articulated and mitigated.
Items for discussion outside of committee Date of next	Consistency across divisions in the area of quality governance to be taken through quality and safety committee. 13 July 2021
meeting	• 13 July 2021